---
title: "Akeso’s AK120 Phase II Completion Adds New Momentum to Its Atopic Dermatitis Pipeline"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/279466421.md"
description: "Akeso’s AK120 Phase II Completion Adds New Momentum to Its Atopic Dermatitis Pipeline"
datetime: "2026-03-17T16:30:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279466421.md)
  - [en](https://longbridge.com/en/news/279466421.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279466421.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/279466421.md) | [English](https://longbridge.com/en/news/279466421.md)


# Akeso’s AK120 Phase II Completion Adds New Momentum to Its Atopic Dermatitis Pipeline

Akeso’s AK120 Phase II Completion Adds New Momentum to Its Atopic Dermatitis Pipeline

### 相關股票

- [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md)
- [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-HK/quote/513060.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md)
- [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-HK/quote/159615.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md)
- [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md)
- [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-HK/quote/159892.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md)
- [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md)
- [AKESO (09926.HK)](https://longbridge.com/zh-HK/quote/09926.HK.md)
- [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md)
- [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md)
- [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md)

## 相關資訊與研究

- [Novo Nordisk, United Bio-Technology Report Positive Mid-stage Clinical Data for UBT251 in China](https://longbridge.com/zh-HK/news/280426128.md)
- [Xuanzhu’s Breast Cancer Drug Bireociclib Delivers Strong Phase 3 Results Published in JAMA Oncology](https://longbridge.com/zh-HK/news/280309450.md)
- [CSPC Pharma Gets China Nod for Obesity Drug Trial](https://longbridge.com/zh-HK/news/279944953.md)
- [Kintor Pharmaceutical Delays Board Meeting to Approve 2025 Annual Results](https://longbridge.com/zh-HK/news/280140223.md)
- [22:20 ETHenlius informa sus resultados de 2025: Crecimiento sostenido tanto en ingresos como en beneficios](https://longbridge.com/zh-HK/news/280085895.md)